Pyridone and aza-pyridone compounds and methods of use

A compound selected from Formula I:

• or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein:
• R1 is H, D, F, Cl, CN, —NH2, —NHCH3, —N(CH3)2, —OH, —OCH3, —OCH2CH3, —OCH2CH2OH, heteroaryl selected from imidazolyl and pyrazolyl, heterocyclyl selected from oxetanyl and azetidinyl, and C1-C3 alkyl;
• R2, R3 and R4 are independently selected from H, D, F, Cl, —NH2, —NHCH3, —N(CH3)2, —OH, —OCH3, —OCH2CH3, —OCH2CH2OH, and C1-C3 alkyl;
• R5 is optionally substituted C6-C20 aryl, C3-C12 carbocyclyl, C2-C20 heterocyclyl, C1-C20 heteroaryl, —(C6-C20 aryl)-(C2-C20 heterocyclyl), —(C1-C20 heteroaryl)-(C2-C20 heterocyclyl), —(C1-C20 heteroaryl)-(C1-C6 alkyl), or —(C1-C20 heteroaryl)-C(═O)—(C2-C20 heterocyclyl);
• R6 is H, F, —NH2, —OH, or optionally substituted C1-C3 alkyl;
• X is S, S(═O), S(═O)2, N, NR6, O, or CR7;
• R7 is independently selected from H, D, F, Cl, —CH3, —CH2CH3, —CN, —CH2F, —CHF2, —CF3, —NH2, —OH, and —OCH3;
• Y1 and Y2 are independently selected from CR6 and N;
• Z1, Z2, Z3, and Z4 are independently selected from C, CR7, and N;
• Z5 is —CR3═N—;
• one of Z1 and Z2, or X and Z1, where X is not S, S(═O), or S(═O)2, forms a five-, six-, or seven-membered aryl, carbocyclyl, heterocyclyl or heteroaryl ring;
• where alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from D, F, Cl, Br, I, —CH3, —CH2CH3, —CH2CH(CH3)2, —CH2OH, —CH2CH2OH, —C(CH3)2OH, —CH(OH)CH(CH3)2, —C(CH3)2CH2OH, —CH2CH2SO2CH3, —CH2OP(O)(OH)2, —CN, —CH2F, —CHF2, —CF3, —CO2H, —COCH3, —CO2CH3, —CO2C(CH3)3, —COCH(OH)CH3, —CONH2, —CONHCH3, —CON(CH3)2, —C(CH3)2CONH2, —NO2, —NH2, —NHCH3, —N(CH3)2, —NHCOCH3, —N(CH3)COCH3, —NHS(O)2CH3, —N(CH3)C(CH3)2CONH2, —N(CH3)CH2CH2S(O)2CH3, ═O, —OH, —OCH3, —OCH2CH2N(CH3)2, —OP(O)(OH)2, —S(O)2N(CH3)2, —SCH3, —CH2OCH3, —S(O)2CH3, cyclopropyl, azetidinyl, 1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino, azetidin-1-ylmethyl, oxetanyl, and morpholino.